Table 1 and Table S1 show their baseline characteristics. The median age was 59.5 (range 41–85). Most patients had Child–Pugh (CP) grade A cirrhosis (83.3%), and 31% were of Albumin-Bilirubin (ALBI) grade 1. About 88.1% had hepatitis B-related HCC. Notably, 64.3% of analyzed patients received single-agent cabozantinib (n = 27), while the remaining 35.7% patients used cabozantinib as add-on therapy to ongoing ICIs (anti-PD1 with or without anti-CTLA-4) (Table S2). This evidence concerns the gene ALB and hepatitis B virus infection.